Achaogen (NASDAQ:AKAO) major shareholder Robert W. Duggan bought 102,849 shares of the company’s stock in a transaction on Friday, April 27th. The shares were acquired at an average cost of $12.96 per share, for a total transaction of $1,332,923.04. Following the completion of the acquisition, the insider now directly owns 7,028,153 shares of the company’s stock, valued at approximately $91,084,862.88. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Achaogen stock opened at $13.09 on Friday. The stock has a market cap of $578.71, a PE ratio of -4.13 and a beta of 1.04. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.83 and a quick ratio of 4.83. Achaogen has a one year low of $9.83 and a one year high of $27.49.

Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.21). The firm had revenue of $1.87 million for the quarter, compared to the consensus estimate of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. equities research analysts predict that Achaogen will post -3.48 EPS for the current year.

A number of brokerages have weighed in on AKAO. SunTrust Banks dropped their target price on shares of Achaogen to $27.00 and set a “buy” rating on the stock in a report on Wednesday, January 3rd. Zacks Investment Research cut shares of Achaogen from a “hold” rating to a “sell” rating in a report on Monday, February 5th. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. William Blair reissued an “outperform” rating on shares of Achaogen in a report on Wednesday, February 28th. Finally, Wedbush reissued an “outperform” rating and set a $22.00 target price (down from $28.00) on shares of Achaogen in a report on Wednesday, February 14th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.56.

Several institutional investors have recently added to or reduced their stakes in AKAO. Wells Fargo & Company MN grew its position in shares of Achaogen by 34.3% during the third quarter. Wells Fargo & Company MN now owns 33,213 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 8,483 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Achaogen by 154.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 122,684 shares of the biopharmaceutical company’s stock valued at $1,957,000 after buying an additional 74,384 shares in the last quarter. Hikari Power Ltd grew its position in Achaogen by 100.0% in the 4th quarter. Hikari Power Ltd now owns 60,000 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 30,000 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in Achaogen in the 4th quarter valued at about $177,000. Finally, Engineers Gate Manager LP bought a new position in Achaogen in the 4th quarter valued at about $412,000. Institutional investors and hedge funds own 77.41% of the company’s stock.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Insider Buying and Selling by Quarter for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.